172 related articles for article (PubMed ID: 23086432)
1. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).
Alexander BM; Wang M; Yung WK; Fine HA; Donahue BA; Tremont IW; Richards RS; Kerlin KJ; Hartford AC; Curran WJ; Mehta MP
J Neurooncol; 2013 Jan; 111(1):33-9. PubMed ID: 23086432
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
[TBL] [Abstract][Full Text] [Related]
3. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
[TBL] [Abstract][Full Text] [Related]
4. Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.
Videtic GM; Gaspar LE; Zamorano L; Stitt LW; Fontanesi J; Levin KJ
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):963-8. PubMed ID: 11704318
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
6. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.
Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL
J Neurooncol; 2004; 67(1-2):191-200. PubMed ID: 15072467
[TBL] [Abstract][Full Text] [Related]
7. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.
Colman H; Berkey BA; Maor MH; Groves MD; Schultz CJ; Vermeulen S; Nelson DF; Mehta MP; Yung WK;
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):818-24. PubMed ID: 16887285
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.
Robins HI; Won M; Seiferheld WF; Schultz CJ; Choucair AK; Brachman DG; Demas WF; Mehta MP
Neuro Oncol; 2006 Jan; 8(1):47-52. PubMed ID: 16443947
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
Turner CD; Chi S; Marcus KJ; MacDonald T; Packer RJ; Poussaint TY; Vajapeyam S; Ullrich N; Goumnerova LC; Scott RM; Briody C; Chordas C; Zimmerman MA; Kieran MW
J Neurooncol; 2007 Mar; 82(1):95-101. PubMed ID: 17031553
[TBL] [Abstract][Full Text] [Related]
11. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Butowski N; Chang SM; Lamborn KR; Polley MY; Pieper R; Costello JF; Vandenberg S; Parvataneni R; Nicole A; Sneed PK; Clarke J; Hsieh E; Costa BM; Reis RM; Hristova-Kazmierski M; Nicol SJ; Thornton DE; Prados MD
Neuro Oncol; 2011 Dec; 13(12):1331-8. PubMed ID: 21896554
[TBL] [Abstract][Full Text] [Related]
12. Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma?
Gupta T; Nair V; Paul SN; Kannan S; Moiyadi A; Epari S; Jalali R
J Neurooncol; 2012 Aug; 109(1):195-203. PubMed ID: 22555992
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
14. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.
Evans SM; Putt M; Yang XY; Lustig RA; Martinez-Lage M; Williams D; Desai A; Wolf R; Brem S; Koch CJ
J Neurooncol; 2016 Apr; 127(2):391-400. PubMed ID: 26746692
[TBL] [Abstract][Full Text] [Related]
15. Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification.
Press RH; Shafer SL; Jiang R; Buchwald ZS; Abugideiri M; Tian S; Morgan TM; Behera M; Sengupta S; Voloschin AD; Olson JJ; Hasan S; Blumenthal DT; Curran WJ; Eaton BR; Shu HG; Zhong J
Cancer; 2020 Jul; 126(14):3255-3264. PubMed ID: 32342992
[TBL] [Abstract][Full Text] [Related]
16. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW
Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
18. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
19. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma.
Li J; Wang M; Won M; Shaw EG; Coughlin C; Curran WJ; Mehta MP
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):623-30. PubMed ID: 20888136
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
Kong XT; Nguyen NT; Choi YJ; Zhang G; Nguyen HN; Filka E; Green S; Yong WH; Liau LM; Green RM; Kaprealian T; Pope WB; Nghiemphu PL; Cloughesy T; Lassman A; Lai A
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1195-1203. PubMed ID: 29722661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
